Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-34879
Titel: Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
VerfasserIn: Sabet, Amir
Mader, Nicolai
Bittenbring, Jörg Thomas
Khreish, Fadi
Grünwald, Frank
Biersack, Hans Jürgen
Ezziddin, Samer
Sprache: Englisch
Titel: Pharmaceuticals
Bandnummer: 14
Heft: 10
Verlag/Plattform: MDPI
Erscheinungsjahr: 2021
Freie Schlagwörter: peptide receptor radionuclide therapy
PRRT
neuroendocrine tumor
NET
peripheral blood stem cell collection
PBSC
hematotoxicity
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Peptide receptor radionuclide therapy (PRRT) of metastatic neuroendocrine tumors (NET) can be successfully repeated but may eventually be dose-limited. Since 177Lu-DOTATATE dose limitation may come from hematological rather than renal function, hematological peripheral blood stem cell backup might be desirable. Here, we report our initial experience of peripheral blood stem-cell collection (PBSC) in patients with treatment-related cytopenia and therefore high risk of bone-marrow failure. Five patients with diffuse bone-marrow infiltration of NET and relevant myelosuppression (≥grade 2) received PBSC before one PRRT cycle with 177Lu-DOTATATE (7.6 ± 0.8 GBq/cycle). Standard stem-cell mobilization with Granulocyte-colony stimulating factor (G-CSF) was applied, and successful PBSC was defined as a collection of >2 × 106/kg CD34+ cells. In case of initial failure, Plerixafor was administered in addition to G-CSF prior to apheresis. PBSC was successfully performed in all patients with no adverse events. Median cumulative activity was 44.8 GBq (range, 21.3–62.4). Three patients had been previously treated with PRRT, two of which needed the addition of Plerixafor for stem-cell mobilization. Only one of five patients required autologous peripheral blood stem-cell transplantation during the median follow up time of 28 months. PBSC collection seems to be feasible in NET with bone-marrow involvement and might be worth considering as a backup strategy prior to PRRT, in order to overcome dose-limiting bone-marrow toxicity.
DOI der Erstveröffentlichung: 10.3390/ph14101022
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-348799
hdl:20.500.11880/31896
http://dx.doi.org/10.22028/D291-34879
ISSN: 1424-8247
Datum des Eintrags: 26-Okt-2021
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Innere Medizin
M - Radiologie
Professur: M - Prof. Dr. Samer Ezziddin
M - Keiner Professur zugeordnet
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
pharmaceuticals-14-01022-v2.pdf497,49 kBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons